This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Edoxaban was at least as effective as warfarin in preventing thromboembolism after bioprosthetic valve replacement in the ENBALV trial, but the event rate was too low to draw definitive conclusions.
Medscape Medical News